The company is not selling any shares of common stock under this prospectus and will not receive any proceeds from the sale by the selling ...

ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on January 2, 2025 ...

Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...

Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies ...

Olema Pharmaceuticals Inc (OLMA) stock saw a modest uptick, ending the day at $5.83 which represents a slight increase of $0.22 or 3.92% from the prior close of $5.61. The stock opened at $5.61 and ...

A Pulitzer Prize-winning weekly covering West Marin, including the towns of Point Reyes Station, Inverness, Bolinas, Stinson Beach, Marshall, Nicasio, Lagunitas, Woodacre, San Geronimo, Forest Knolls, ...

Geode Capital Management LLC reduced its stake in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Free Report) by 11.8% ...

Novartis NVS announced positive top-line results from the late-stage STEER study on experimental candidate intrathecal ...